**2015 Review: (n = 49)**

**Mahy *et al. AIDS***

**2017**

Years covered: 2012-2015

🡪 Studies excluded **(n = 13)B**

Studies included in final meta-analysis **(n = 36)**

**2018 Review: (n = 23)**

**Stover *et al. AIDS***

**2019**

Years covered: 2015-2018

🡪 Studies excluded **(n = 2)C**

Studies included in final meta-analysis **(n = 20)**

**2012 Review: (n = 38)**

**Rollins *et al.* *Sex Trans Infect* 2012**

Years covered: 1990-2012

🡪 Studies excluded **(n = 7)A**

Studies included in final meta-analysis **(n = 30)**

**Previous Reviews**

*Previous reviews informed the 2024 review approach*

**2024 Systematic Review**

**1 January 2018 to 8 February 2024**

Studies from databases/registers **(n = 12,588)**

Embase (n=4673)

PubMed (n=3878)

CINAHL (n=1311)

CENTRAL (n=770)

World Health Organization (WHO) (n=97)

Unspecified (n=1859)

Duplicates removed **(n = 5,858)**

Titles and abstracts screened **(n = 6,730)**

Titles and abstracts excluded **(n = 6,306)**

**2024 Systematic Review**

Full texts assessed for eligibility **(n = 424)**

Studies excluded **(n = 400)**

Primary reason for exclusion:

* Study aggregated heterogenous groups, primarily on ART use (n=172, 43%)
* Wrong HIV test time, or wrong paediatric age group (n=87, 22%)
* Full text not available (n=56, 14%)
* Wrong study design (n=48, 12%)
* Rate of MTCT not reported (n=32, 8%)
* Birthing persons were co-infected with HIV and another illness (n=5, 1%)

Studies from 2024 review that were extracted and added to the meta-analysis **(n = 24)**

**Total number of studies included in the final 2024 meta-regression (n = 110)**

**Model 1 (n = 17)**

**Untreated WLHIV**

Previous review (2018)

(n = 15)

Added in 2024

(n = 2)

**Region**

ESA (n = 9)

WCA (n = 2)

AP (n = 1)

WCENA (n = 2)

MENA (n = 1)

Multiple regions (n = 2)

**VLS (n = 15)**

**VL at delivery**

Previous review (2018)

(n = 11)

Added in 2024

(n = 4)

**Region**

ESA (n = 3)

AP (n = 1)

WCENA (n = 11)

**Model 4 (n = 16)**

**Lifelong ART, breastfeeding VT**

Previous review (2018)

(n = 11)

Added in 2024

(n = 5)

**Region**

ESA (n = 12)

WCENA (n = 2)

Multiple regions (n = 2)

**Model 3 (n = 57)**

**Lifelong ART,**

**perinatal VT**

Previous review (2018)

(n = 39)

Added in 2024

(n = 18)

**Region**

ESA (n = 23)

WCA (n = 2)

LAC (n = 1)

AP (n = 5)

WCENA (n = 23)

Multiple regions (n = 3)

**Model 2 (n = 58)**

**Seroconversion and short course PMTCT**

Previous review (2018)

(n = 53)

Added in 2024

(n = 5)

**Region**

ESA (n = 41)

WCA (n = 6)

LAC (n = 1)

AP (n = 4)

WCENA (n = 3)

Multiple regions (n = 3)

**2024 Meta-analysis**